PharmaVoice 10. März 2026 Executives want in, but researchers want out — how pharma’s US job picture is changing
PharmaVoice 9. März 2026 The first KRAS drugs have been sluggish on the market. Will the next generation fare better?
PharmaVoice 4. März 2026 Inside the race to thwart the dramatic rise in early-onset colorectal cancer
PharmaVoice 3. März 2026 J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks